Business · 21/01/2026Updated: 10/16/2026 · 1 min read
FDA Approves RHAPSIDO (Remibrutinib) for Rare Pediatric Disease Priority Review Voucher
Summary
The FDA has approved RHAPSIDO (remibrutinib), a product redeeming a priority review voucher, following the issuance of a notice by the agency on September 30, 2025.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →